Manning & Napier Life Sciences Series Fund

Class No Load (EXLSX)
Scorecard
1 / 5 Stars
Lipper
1 1 4 3 1
Zacks Investment Research
4 (Sell)
Standard & Poor's
1 / 5 Stars
TheStreet.com
---

U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Manning & Napier funds

See full Health rankings

See more fund rankings

Performance

The fund has returned 23.00 percent over the past year, 13.09 percent over the past three years, 23.15 percent over the past five years, and 8.44 percent over the past decade.

Trailing Returns Updated 02.28.2014
Year to date 1.4%
1 Year 23.0%
3 Years (Annualized) 13.1%
5 Years (Annualized) 23.1%
10 Years (Annualized) 8.4%

See more EXLSX performance

Summary

The investment seeks to provide long-term growth by investing principally in the common stocks of companies in the life sciences industry. The fund will invest, under normal circumstances, at least 80% of its net assets in securities of companies involved in the life sciences industry. Examples of the companies in which the Series may invest include those in the following areas: pharmaceuticals, biotechnology, medical products and supplies, health care services, and environmental services. The fund may invest in U.S. and foreign stocks, including those in emerging markets, ADRs and other U.S. dollar denominated securities of foreign issuers.

Fees

Fees are Low compared to funds in the same category.
Manning & Napier Life Sciences Series Fund has an expense ratio of 1.16 percent.

See more EXLSX fees

Risk

Risk is Above Average compared to funds in the same category according to Morningstar.

See more EXLSX risk